Accurately diagnosing disease inPeople, Pets and ProductionAnimals BEFORE symptoms

appear

February 2018

David Gordon, CEODr. Christoph Sensen, CSO

This Presentation is based upon information supplied by CNA Diagnostics Inc.(“CNAD” or the "Company") solely for use by prospective strategic partnersand/or investors in the company. This Presentation does not purport to be all-inclusive or to contain all of the information that a prospective strategic partnerand/or investor may desire. No representation or warranty is made as to theaccuracy or completeness of any of the information contained herein. Eachrecipient of this memorandum agrees that all of the information containedherein is of a confidential nature, that he will treat it in a confidential manner,and that he will not directly or indirectly, disclose, or permit his agents oraffiliates to disclose, any of such information without the prior written consent ofthe Company. Neither this Presentation, nor its delivery to any prospectivestrategic partner and/or investor, shall constitute an offer to sell or thesolicitation of an offer to buy any securities of the Company, nor shall thisPresentation be construed to indicate that there has been no change in theaffairs of the Company. This Presentation contains "forward-lookinginformation", which is disclosure regarding possible events, conditions orfinancial performance that is based on assumptions about future economicconditions and courses of action. In particular, the forward-looking informationin this presentation includes: statements regarding timing and outcomes of

research, development, and commercialization activities, financing activities,protection of intellectual property, market share and growth. Actual results mayvary from the forward-looking information in this presentation. Material riskfactors that could cause actual results to differ materially from the forward-looking information include: (i) CNAD’s ability to develop commercially viableproducts; (ii) CNAD’s ability to achieve profitability; (iii) CNAD’s ability toproduce and market its products; (iv) CNAD’s ability to obtain regulatoryapproval of its products; (v) CNAD’s ability to protect its intellectual property;(vi) competitive and alternative technologies; and (vii) CNAD’s ability to obtainfinancing to support its operations. The material factors or assumptions thatwere used to develop the forward-looking information in this presentationinclude: our ability to achieve research and development objectives, timing ofproposed commercialization plans, ability to protect intellectual property, abilityto secure needed financing or our ability to develop sufficient margins in thebusiness through development of proposed technology or other means.CNAD's views regarding possible events, conditions or financial performancemay change. However, CNAD does not intend to update the forward-lookinginformation in this presentation, except as required by applicable securitieslegislation.

Disclaimer

• Molecular diagnostic company with a proprietary technology platform + significant in house expertise that accurately identifies diseases in People, Pets and Production Animals BEFORE symptoms appear.

• Third party validation: Canadian military collaboration on human sepsis. Kills 5.1M annually worldwide. $24B annual health care costs in USA. Once symptoms appear chance of death increase 8% per hour. Phase 1a study– identified all 22 patients 2-3 days BEFORE the symptoms appeared.

• Developing and monetizing an IP portfolio of diagnostic tests.• Process is standardized, repeatable, and scalable.• To date 100% success rate in the identification of motifs for four diseases in humans (sepsis ~3 days), cattle

(BSE – 10 months), elk (CWD – 10 months) and rats (radiation – 1 hour).• Business model is to stay within our niche and employ channel partners for distribution.• Low SG&A costs. Burning only $50k CAD per month plus R&D. Full wet lab benefits and large research team

through intelligent partnerships.• Third party validation: license agreement for the distribution of production animal diseases with major European

pharma for 67 countries.• Industry is attracting capital. Everyone is focused on human cancer.• Test pipeline is ready to expand aggressively.

At a Glance

Mammal Challenge Identification Value Commercial Use

Rats Radiation Identify impact within 1 hour Proof of concept None yet

Elk Chronic wasting 10 months before symptoms Proof of concept None

Beef Cattle Bovine Spongiform Encephalopathy

10 months before symptoms

Prevents transfer to humans and other animals Beef Importing Nations

Human Bacterial Sepsis Up to 3 days before symptoms

Saves lives~20% death rate

1 million infections in USA each year

Wide spread, plans for screening diagnostic being developed with MedUni Graz

Proof of Concept

Body responds to challenges as it fights to return to normal.

Cells die as part of normal life (Apoptosis). DNA information

regarding cell activity is released into the blood and contain the genomic regions

that were transcribed just before the cell died.

CNAD identify long chain DNA biomarkers specific to the host’s

response to the challenge.Markers are usually present

before the clinical signs appear.Biomarkers are patented.

α<0.0001

Circulating Nucleic Acids (CNA)

Tests easily run using standard PCR equipment. Limited specific expertise

required to administer.

+8 years to develop proprietary technology

Workflow

Blood Collection

Isolation and Amplification

of DNA

High-throughput Sequencing

of DNA

Bio-informaticalAnalysis

Identification of Marker Sequences

by PCR

• Highest burden of death and medical expenses in hospitals worldwide.– Most expensive in-patient cost in U.S. hospitals - $24B annually.– Once signs of the disease appear ~20-30% chance of death.

• 1.6M cases annually in U.S. with 500,000 deaths.• Expensive and unpredictable to health insurers.• Over 300 different forms of Sepsis. i.e. bacterial, fungal, etc.• Competitors have developed solutions to diagnose specific forms

of sepsis a patient has contracted.– These tests are not commonly run until clinical signs appear.

IP Portfolio - Sepsis Opportunity• CNAD is working with Canadian Department of National

Defense. Mar. 2015 – Completed initial trial utilizing 22 test Sepsis patients and a control group of 51 people.

• CNAD is working with Medical University of Graz• 66 Candidiasis samples

• Results:

– 100% identification of sepsis in patients.– Diagnosed infection up to 3 days before any clinical

signs appeared.

• Next steps – Phase 1b bacterial – 33 E. Coli, 27 S.Aureus. Phase 1 Fungal. 66 Candidiasis.

• Goal – Biomarkers identified and provisional patents filed by end of 2018.

Human Sepsis PCR Status: Infected Individuals vs. Controls

The cycle at which fluorescence from amplification exceeds the background fluorescenceThe lower the CQ value is the higher is the amount of targetCQ difference of 3.3 means 10 fold higher or lower amount of target!Still under evaluation (normalization needed)

Corporate Strategy - Positioning

Deploy funds to animal diseases• Quick to market• Quick to cash flow• Lower risk to investors• Only diseases/conditions with high economic

impact

Selectively investigate high impact human diagnostics• Massive upside potential• Use non-dilutive funds as much as

possible to reduce risked capital

Barbell Strategy

Corporate Strategy – Business OfferingIdentification of

biomarkers related to diseases or conditions

CRO Pure Distribution Collaborative

• Margin earned on studies

• IP assigned• Royalty tail

• CNAD keeps IP• Royalty share

of Net Sales• CNAD bears

costs

• CNAD keeps IP• Samples,

distribution, costs sharing, disease ID are unique to deal

Appropriate for large enterprises

Unique deal termsAppropriate for low risk appetite

Corporate Strategy - Partnering

Product Distribution:• Use of channel partners.

• 67 country distribution agreement with Laboratorios Maymo for bovine tests

• Limited sales costs.• Multiple partners (never just one). • Access to new distribution partners via Director

networks, contracted sell side networks, and other existing contacts.

• Accessing large scale manufacturing (sepsis).• In discussion with mid-sized pharma and vet

operations.• Opening doors to government at high levels.

Samples for New Diagnostic Tests:• Securing human sepsis samples through

Medical University of Graz, Canadian Military. • Agreement with Vetmed Vienna.• Access to one of largest European biobanks.• Scientific Advisory Committee.• Collaborative partnerships.

Corporate Strategy - Structuring for Exit• Working with Board and Advisors to structure company for maximum sale

value.• Considering ways to earn multiple high value exits for investors via

corporate structure.

• Contracts with partners include exit options (for ease of future transactions).

• Continue to act as pubco for investor transparency and confidence.• Audited financial statements• Good governance practices in place

• Considering methods to create liquidity windows for those that want out early.

• Share buybacks on future rounds?

• Exploring Dual Process• Strategic Sale(s)• Go Public (carefully)

• Consider timing. • Expect >$1,000,000 in additional costs to be borne by shareholders

IF this is the preferred route.• Capital to dictate direction.

Financing

Small Bridge Round Open:• Raise $2M CAD @ $0.50 CAD/ Common Avoting

share• $9.1M pre-money• 22% of company post money [f.d.]• AB shareholders get tax credit

Activity Estimated Cost [$CAD]

Johne’s Regulatory Approvals $100,000

Sepsis [Bacterial and Candidiasis] Biomarker Identification

$600,000

Companion Animal Test Development (Start)

$600,000

High-Throughput Machine Development

$250,000 [~$800,000in Grants]

Exploratory Research / New Targets $50,000

Necessary Overheads $225,000

Raise Fees $140,000

Total Estimated Costs to Dec 2018 $1,965,000

• Existing shareholders and insiders picked up all expiring warrants.

• Expansion is a function of available capital. Identifying many diseases of relevance. Managing Growth.

• Financial statements are audited.

16.4M Common Shares 1.4M Options1.3M Warrants

19.1M Fully Diluted

Corporate Structure

10

Insider Ownership – 40% Paid in Capital – $2.6M Debt – $0 Cash – $400k

$9.5M pre-money valuation (f.d)

Proposed Exits and DCF

Terminal Value Method: Free Cash FlowMultiple Used: 4.0x (~23X average for trading comps. Abaxis, Idexx 27x)Terminal Value: $725MDiscount Rate to show $0.50 stock: 185%

ROI on $0.50 round: 80X (Terminal Sale Value Only)

Projected Annual Forecast2018 2019 2020 2021 2022

Total Revenues 2,019,125 12,072,048 40,637,904 139,289,600 276,771,995 EBIT (506,140) (1,402,829) 22,558,581 116,930,866 250,516,113 Capital expenditures (net of asset sales) - (5,000,000) - - - Unlevered free cash flows (818,903) (7,537,067) 18,703,553 82,712,439 181,423,526 Discount factor 0.960 0.738 0.568 0.437 0.336 Present value of free cash flows (786,029) (5,565,000) 10,622,910 36,136,566 60,971,419

Sum of present values of FCFs 101,379,866

**Disclaimer: Early Modelling given what we know today. Please refer to Slide 2 Disclaimer**

**Disclaimer: Early Modelling. This is an estimate. Please refer to Slide 2 Disclaimer**

David L. Gordon CEODavid is a business and financial professional with +15 years experience optimizing business performance and effectively deploying capital to maximize an organization’s potential. David has co-managed a $3.0 billion North American equity fund; conducted the turnaround of a municipal water utility including direct oversight and responsibility of $1.4 billion capex over 4 years, $330 million annual OPEX, and a team of 20 FTEs. David has managed an $85 million land development portfolio, raised over $125 million (in collaboration with partners) for SMEs and small pubcos, and conducted complex private equity transactions for middle market companies in the range of $10-$60 million while investment banking with CIBC. David has participated in the success of Resverlogix($2.80 to >$28) and Neptune Biotech ($1.11 to >$6.00) as well as many other micro-cap public companies. He holds a Chartered Financial Analyst (CFA) designation and is a Project Management Professional (PMP) and well as the Top Graduate within his Bcomm program. David is a published author on strategy execution. David is experienced in the unique challenges facing small and quickly growing entities and loves bringing disruptive technologies to market.

Dr. Christoph W. Sensen CSOA founding member of CNA Diagnostics Inc., Dr. Sensen is a University Professor for Computational Biotechnology at the Graz University of Technology in Austria and an Adjunct Professor at the University of Calgary’s Faculty of Medicine, Department of Biochemistry and Molecular Biology. He participated in several large-scale Genome Research programs, including two for the development of markers for CWD and BSE, and co-Author on more than 100 peer-reviewed articles and has edited or published six books in the field of Genome Research and Bioinformatics. Dr. Sensen is a reviewer for granting agencies and Journals;and Chief Editor at Journal of Biotechnology (Elsevier).

Previously he worked for seven years as a Research Officer at the National Research Council of Canada’s Institute for Marine Biosciences (NRC-IMB) and as a visiting scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg (13 months). He studied Biology in Mainz, Düsseldorf and Cologne and obtained a Dr. rer. nat. degree from the University of Cologne in 1994.

Management

11

Dennis L. Nerland, QC Director

Dr. Greg Andrews Chairman, Director

Dr. David Chalack Scientific Advisor

Dr. G. Kee Jim Director

Alec Milne Director

Dr. Robert B. Church Scientific Advisor

Independent Board and Advisors

12

Mr. Todd WallachDirector

Appendix

Johne’s StatusScientific Status Update:• Currently, 9 discriminative CNA region candidates

being investigated, filtered from more than 60 initial targets.

• First results show a discrimination between infected and controls in more than one PCR round.

• PCR analysis for additional marker region candidates is in progress.

• Development of a new normalization approach is in progress as well.

• Able to identify 6 controls, including one tested 52x negative with gold standard tests, were actually infected with mycobacterium avium!

Business Overview:• The market is seeking a solution.

• production losses, export problems, animal breeding issues.• Ireland announces eradication program.

• Consumers to question milk supply?• Japan / Australia importing relationship issues• Gold Standard: Current blood and stool tests are

only 30-60% effective. (useless)• > €2.0B annual impact in contracted distribution

territories. $5.0B USD worldwide.• Potential partners expressing interest in Canada,

USA, and South America.

Bovine Respiratory Disease status• DNA Sequencing has been completed• Mapping to genomic assembly UMD 3.1.1

• Currently in progress• Dataset:

• 941 samples (~ 0.6 TB)• 654 disease samples from 161 animals• 287 control samples from 72 animals

• Sorted by • Label• Animal• Sampling time point• Disease state and treatment

• Market is seeking a solution. Verified by large pharma.• Very limited effective testing methods. Observation of

clinical signs and use of antibiotics.• >$4.0B annual economic impact worldwide. Most

economically significant disease in North American cattle industry.

• $23-$150 loss per cow plus treatment costs up to $45.• CNAD is creating a test that can identify the disease

upon entry to the feedlot with high sensitivity/specificity. Results in 2-3 hours.

• Developing rapid testing machine to employ chute side testing. >1 year away still.